Promising Clinical Results

The initial results of the prospective European ESPOIR Trial over a period of up to 3 years proved “Cell-free human pulmonary valve, Espoir PV” to be safe and efficient in a multicentre setting with excellent short-term haemodynamics. The performance is superior to other widely used pulmonary valve prosthesis in cohorts matched for age, type of congenital heart defect and the number of previous procedures.